CYTOSORBENTS CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
CYTOSORBENTS CORPORATION (CTSO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.40% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-30
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-03-31 was 1.03%, a 9.57% increase year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2020-03-31 was 0.94%, a 63.98% decline year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2019-03-31 was 2.61%, a 6.12% decline year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2018-03-31 was 2.78%, a 25.62% increase year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.40%, a 5.38% decline from fiscal 2024.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.65%, a 2.31% decline from fiscal 2023.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.76%.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.39%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.40% 10-K · filed 2026-03-30 | |||
| 2024-12-31 | 4.65% 10-K · filed 2026-03-30 | |||
| 2023-12-31 | 4.76% 10-K · filed 2025-03-31 | |||
| 2021-12-31 | 1.39% 10-K · filed 2022-03-10 | |||
| 2021-09-30 | 1.12% 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | 1.05% 10-Q · filed 2021-08-03 | |||
| 2021-03-31 | 1.03% 10-Q · filed 2021-05-04 | |||
| 2020-09-30 | 0.36% 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | 0.96% 10-Q · filed 2020-08-04 | |||
| 2020-03-31 | 0.94% 10-Q · filed 2020-05-05 | |||
| 2019-09-30 | 2.60% 10-Q · filed 2019-11-05 | |||
| 2019-06-30 | 2.60% 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | 2.61% 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | 3.11% 10-K · filed 2019-03-07 | |||
| 2018-09-30 | 3.00% 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | 2.90% 10-Q · filed 2018-08-02 | |||
| 2018-03-31 | 2.78% 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | 2.21% 10-K · filed 2018-03-08 | |||
| 2017-09-30 | 1.85% 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | 2.21% 10-Q · filed 2017-08-07 | |||
| 2017-03-31 | 2.21% 10-Q · filed 2017-05-08 | |||
| 2016-12-31 | 1.85% 10-K · filed 2017-03-03 | |||
| 2016-09-30 | 1.81% 10-Q · filed 2016-11-07 | |||
| 2016-06-30 | 1.81% 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | 1.81% 10-Q · filed 2016-05-09 | |||
| 2015-12-31 | 1.95% 10-K · filed 2016-03-09 | |||
| 2014-12-31 | 2.06% 10-K · filed 2015-03-31 | |||
| 2013-12-31 | 1.89% 10-K · filed 2014-03-31 | |||
| 2013-09-30 | 1.90% 10-Q · filed 2013-11-06 | |||
| 2013-06-30 | 1.90% 10-Q · filed 2013-08-14 | |||
| 2013-03-31 | 1.90% 10-Q · filed 2013-05-15 | |||
| 2012-12-31 | 1.90% 10-K · filed 2013-04-03 | |||
| 2012-09-30 | 1.90% 10-Q · filed 2012-11-21 | |||
| 2012-06-30 | 1.90% 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |